Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer J Clinicians 2013; 63(1):11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet 2011; 378(9804):1727-1740; http://dx.doi.org/10.1016/s0140-6736(10)62101-0
   PubMed Web of Science ®Google Scholar
• Spaks A, Svirina D, Spaka I, Jaunalksne I, Breiva D, Tracums I, Krievins D. CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment. Biomarkers 2016; 21(5):474-8: 1-4; PMID:27098116; http://dx.doi.org/10.3109/1354750X.2016.1172111
   PubMed Web of Science ®Google Scholar
• Stewart RL, Carpenter BL, West DS, Knifley T, Liu L, Wang C, Weiss HL, Gal TS, Durbin EB, Arnold SM, et al. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. Oncotarget 2016; 7(23):34630-42; PMID:27127879; http://dx.doi.org/10.18632/oncotarget.8969
   PubMed Web of Science ®Google Scholar
• Xiao HQ, Tian RH, Zhang ZH, Du KQ, Ni YM. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis. OncoTargets therapy 2016; 9:1471-1476; PMID:27042115; http://dx.doi.org/10.2147/OTT.S96160
   PubMed Web of Science ®Google Scholar
• Bhatia S, Pereira K, Mohan P, Narayanan G, Wangpaichitr M, Savaraj N. Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know. Indian J Radiol Imaging 2016; 26(1):81-91; PMID:27081229; http://dx.doi.org/10.4103/0971-3026.178347
   PubMedGoogle Scholar
• Dinh TK, Fendler W, Chalubinska-Fendler J, Acharya SS, O'Leary C, Deraska PV, D'Andrea AD, Chowdhury D, Kozono D. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol 2016; 11(1):61; PMID:27117590; http://dx.doi.org/10.1186/s13014-016-0636-4
   PubMed Web of Science ®Google Scholar
• Sun XJ, Deng QH, Yu XM, Ji YL, Zheng YD, Jiang H, Xu YP, Ma SL. A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer. BMC Cancer 2016; 16(1):266; PMID:27067521; http://dx.doi.org/10.1186/s12885-016-2234-0
   PubMed Web of Science ®Google Scholar
• Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, Ahn MJ, Ahn YC, Kim K, Kim J. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. Lung Cancer 2016; 96:56-62; PMID:27133751; http://dx.doi.org/10.1016/j.lungcan.2016.03.016
   PubMed Web of Science ®Google Scholar
• Berardi R, Rinaldi S, Santoni M, Newsom-Davis T, Tiberi M, Morgese F, Caramanti M, Savini A, Ferrini C, Torniai M, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget 2016; 7(18):26916-24; PMID:27029035; http://dx.doi.org/10.18632/oncotarget.8309
   PubMed Web of Science ®Google Scholar
• Franks SE, Jones RA, Briah R, Murray P, Moorehead RA. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes 2016; 9(1):134; PMID:26928578; http://dx.doi.org/10.1186/s13104-016-1919-4
   PubMedGoogle Scholar
• Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res 2016; 35(1):70; PMID:27102688; http://dx.doi.org/10.1186/s13046-016-0347-6
   PubMed Web of Science ®Google Scholar
• Zhou BO, Nie J, Yang W, Huang C, Huang YE, Zhao H. Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients. Oncology letters 2016; 11(2):1413-1417; PMID:26893752; http://dx.doi.org/10.3892/ol.2015.4066
   PubMed Web of Science ®Google Scholar
• Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J, Gridelli C. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009; 45(14):2473-2487; PMID:19596191; http://dx.doi.org/10.1016/j.ejca.2009.06.005
   PubMed Web of Science ®Google Scholar
• Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 2009; 54(6):677-687; PMID:19438743; http://dx.doi.org/10.1111/j.1365-2559.2009.03280.x
   PubMed Web of Science ®Google Scholar
• Xu X, Liu S, Lei B, Li W, Lin N, Sheng W, Huang A, Shen H. Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G. Mol Cell Biochem 2013; 383(1–2):1-11; PMID:24013786; http://dx.doi.org/10.1007/s11010-013-1722-7
   PubMed Web of Science ®Google Scholar
• Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999; 47(12):1575-1580; PMID:10567441
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 2010; 29(29):4145-4156; PMID:20514014; http://dx.doi.org/10.1038/onc.2010.166
   PubMed Web of Science ®Google Scholar
• Zhong X, Li M, Nie B, Wu F, Zhang L, Wang E, Han Y. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocarcinoma. Annals Surg Oncol 2013; 20(3):1044-1052; PMID:22592183; http://dx.doi.org/10.1245/s10434-012-2377-4
   PubMed Web of Science ®Google Scholar
• Fei F, Li X, Xu L, Li D, Zhang Z, Guo X, Yang H, Chen Z, Xing J. CD147-CD98hc complex contributes to poor prognosis of non-small cell lung cancer patients through promoting cell proliferation via the PI3K/Akt signaling pathway. Annals Surg Oncol 2014; 21(13):4359-4368; PMID:25084765; http://dx.doi.org/10.1245/s10434-014-3816-1
   PubMed Web of Science ®Google Scholar
• Zeng H, Qiu Y, Qu Y, Liang A, Deng A, Zhang W, Xiu B, Wang H, Wang H. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma 2011; 58(5):449-454; PMID:21745000; http://dx.doi.org/10.4149/neo_2011_05_449
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Sun Q, Feng F, Huhe M, Mi L, Chen Z. Preclinical pharmacokinetics, tolerability, and pharmacodynamics of metuzumab, a novel CD147 human-mouse chimeric and glycoengineered antibody. Mol Cancer Therapeutics 2015; 14(1):162-173; PMID:25376611; http://dx.doi.org/10.1158/1535-7163.MCT-14-0104
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Annals Oncol 2006; 17(Suppl 5):v7-12; PMID:16807468; http://dx.doi.org/10.1093/annonc/mdj941
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51(22):6110-6117; PMID:1718594
   PubMed Web of Science ®Google Scholar
• de Carpeno JC, Baron MG, Aguiar J, Chacon JI, Feliu J, Garcia MJ, Madronal C, Colmenarejo A, Sanchez JJ, Ordonez A, et al. Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Cancer Chemotherapy Pharmacol 2006; 58(2):266-271; PMID:16308698; http://dx.doi.org/10.1007/s00280-005-0143-z
   PubMed Web of Science ®Google Scholar
• He Q, Gao J, Ge S, Wang T, Li Y, Peng Z, Li Y, Shen L. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 2014; 140(9):1575-1583; PMID:24804814; http://dx.doi.org/10.1007/s00432-014-1693-4
   PubMed Web of Science ®Google Scholar
• Torres C, Linares A, Alejandre MJ, Palomino-Morales RJ, Delgado JR, Perales S. Interplay between gemcitabine and erlotinib over pancreatic adenocarcinoma cells. Pancreas 2016; 45(2):269-280; PMID:26495790; http://dx.doi.org/10.1097/mpa.0000000000000452
   PubMed Web of Science ®Google Scholar
• Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, et al. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. Int J Oncol 2015; 47(4):1293-1302; PMID:26252371; http://dx.doi.org/10.3892/ijo.2015.3118
   PubMed Web of Science ®Google Scholar
• Maseki S, Ijichi K, Nakanishi H, Hasegawa Y, Ogawa T, Murakami S. Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma. Mol Clin Oncol 2013; 1(5):918-924; PMID:24649271; http://dx.doi.org/10.3892/mco.2013.159
   PubMedGoogle Scholar
• Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998; 273(13):7770-7775; PMID:9516487; http://dx.doi.org/10.1074/jbc.273.13.7770
   PubMed Web of Science ®Google Scholar
• Persad R, Liu C, Wu TT, Houlihan PS, Hamilton SR, Diehl AM, Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Modern Pathol 2004; 17(7):861-867; PMID:15098015; http://dx.doi.org/10.1038/modpathol.3800146
   PubMed Web of Science ®Google Scholar
• Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41(2):77-88; PMID:19514966; http://dx.doi.org/10.1080/03602530902741828
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6(Suppl 6):7-13; PMID:8718419
   PubMed Web of Science ®Google Scholar
• Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer. Clin Cancer Res 2014; 20(21):5435-5445; PMID:25224279; http://dx.doi.org/10.1158/1078-0432.CCR-14-0542
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC PHARMACOL 2004; 4:8; PMID:15157282; http://dx.doi.org/10.1186/1471-2210-4-8
   PubMedGoogle Scholar
• Gregoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave-Prignot M, Scalliet P. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiotherapy Oncol 2002; 63(3):329-338; PMID:12142097; http://dx.doi.org/10.1016/S0167-8140(02)00106-8
   PubMed Web of Science ®Google Scholar
• Al-Katib AM, Aboukameel A, Ebrahim A, Beck FW, Tekyi-Mensah SE, Raufi A, Ahmed Y, Mandziara M, Kafri Z. Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3beta) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. Exp Hematol Oncol 2014; 3:31; PMID:25937997; http://dx.doi.org/10.1186/2162-3619-3-31
   PubMedGoogle Scholar
• Nancy E, Nianyu L, Bailey K, Fort M, Stevenson R, Jawando R, Salyers K, Jawa V, Narayanan P, Stevens E, et al. Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody. Toxicol Pathol 2013; 41(7):951-969; PMID:23475561; http://dx.doi.org/10.1177/0192623312474727
   PubMed Web of Science ®Google Scholar
• Aras B, Yerlikaya A. Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. Oncol Letters 2016; 11(5):3179-3184; PMID:27123085; http://dx.doi.org/10.3892/ol.2016.4340
   PubMed Web of Science ®Google Scholar
• Mohseni M, Samadi N, Ghanbari P, Yousefi B, Tabasinezhad M, Sharifi S, Nazemiyeh H. Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance. Iranian J Basic Medical Sci 2016; 19(3):300-309; PMID:27114800
   PubMed Web of Science ®Google Scholar
• Xiao TT, Wang YY, Zhang Y, Bai CH, Shen XC. Similar to spironolactone, oxymatrine is protective in aldosterone-induced cardiomyocyte injury via inhibition of calpain and apoptosis-inducing factor signaling. PloS One 2014; 9(2):e88856; PMID:24551180; http://dx.doi.org/10.1371/journal.pone.0088856
   PubMedGoogle Scholar
• Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011; 30:20; PMID:21329503; http://dx.doi.org/10.1186/1756-9966-30-20
   PubMed Web of Science ®Google Scholar
• Hu Z, Lv G, Li Y, Li E, Li H, Zhou Q, Yang B, Cao W. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound. J Exp Clin Cancer Res 2016; 35(1):71; PMID:27102814; http://dx.doi.org/10.1186/s13046-016-0349-4
   PubMed Web of Science ®Google Scholar
• Elfayomy AK, Almasry SM, Attia GM, Habib FA. Enhanced expression of vascular endothelial growth factor and increased microvascular density in women with endometrial hyperplasia: a possible relationship with uterine natural killer cells. Romanian J Morphol Embryol 2015; 56(2 Suppl):725-734; PMID:26429165
   PubMed Web of Science ®Google Scholar